---
document_datetime: 2025-12-02 05:28:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ekterly.html
document_name: ekterly.html
version: success
processing_time: 0.0999746
conversion_datetime: 2025-12-28 05:34:41.029203
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ekterly

[RSS](/en/individual-human-medicine.xml/263495)

##### Authorised

This medicine is authorised for use in the European Union

sebetralstat Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ekterly](#news-on)
- [More information on Ekterly](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ekterly is a medicine used to treat symptoms of hereditary angioedema (swelling) attacks in people aged 12 years and older. People with hereditary angioedema have attacks of rapid swelling that can occur anywhere in the body such as the face, throat, arms, legs or around the gut. These attacks can be life threatening.

Hereditary angioedema is rare, and Ekterly was designated an 'orphan medicine' (a medicine used in rare diseases) on 21 June 2022. Further information on the orphan designation can be found on the EMA [website](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2625) .

Ekterly contains the active substance sebetralstat.

Expand section

Collapse section

## How is Ekterly used?

Ekterly can only be obtained with a prescription and treatment should be prescribed by a doctor experienced in treating people with hereditary angioedema.

The medicine is available as tablets to be taken by mouth. One tablet should be taken at the first signs of an attack. A second tablet may be taken at least 3 hours after the first tablet if the symptoms do not improve, get worse or come back. No more than two tablets should be taken over 24 hours.

For more information about using Ekterly, see the package leaflet or contact your doctor or pharmacist.

## How does Ekterly work?

The active substance in Ekterly, sebetralstat, works by blocking the activity of a protein called kallikrein. In people with hereditary angioedema, kallikrein is overactive and leads to increased levels of another protein called bradykinin. Bradykinin causes blood vessels to widen and become leaky, allowing fluid to build up in the surrounding tissues, which causes angioedema attacks. By blocking kallikrein, Ekterly reduces the amount of bradykinin made during an attack, which prevents it from getting worse.

## What benefits of Ekterly have been shown in studies?

A main study showed that Ekterly can lead to faster improvement of symptoms during hereditary angioedema attacks compared with placebo (a dummy treatment).

The main study involved 110 people aged 12 years and older with hereditary angioedema. Participants were instructed to take one tablet of Ekterly or placebo at the first signs of an attack. They could take a second tablet after at least 3 hours if symptoms had not improved enough or had worsened or come back. The main measure of effectiveness was the time it took for symptoms to start improving after taking the treatment, as determined using the patient global impression of change (PGI-C) scale. The PGI-C scale is a questionnaire that asks patients to rate how much their symptoms have improved or worsened after treatment.

On average, symptoms started improving 1.6 hours after taking the treatment in people given Ekterly, compared with 6.7 hours for those given placebo.

## What are the risks associated with Ekterly?

For the full list of side effects and restrictions with Ekterly, see the package leaflet.

The most common side effects with Ekterly (which may affect up to 1 in 10 people) include headache.

## Why is Ekterly authorised in the EU?

A main study showed that Ekterly is more effective than placebo at relieving symptoms of hereditary angioedema attacks.

At the time of authorisation, Ekterly was the first medicine for hereditary angioedema attacks that could be taken by mouth. This provides a more comfortable option for patients than receiving medicines by injection. Furthermore, a tablet can be taken sooner after a patient begin to develop symptoms of an attack, which could reduce the severity and duration of the attack.

The safety of Ekterly was evaluated in a small number of patients. Episodes of headache with Ekterly were mild to moderate in intensity and went away on their own. Overall, side effects were mild to moderate and considered acceptable. However, there are some uncertainties about the potential for Ekterly to cause QT prolongation (abnormal electrical activity of the heart that affects its rhythm). A warning has therefore been included in the product information for the medicine to highlight this potential risk in people with pre-existing QT prolongation or known risk factors.

The European Medicines Agency therefore decided that Ekterly's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ekterly?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ekterly have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ekterly are continuously monitored. Suspected side effects reported with Ekterly are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ekterly

Ekterly received a marketing authorisation valid throughout the EU on 17 September 2025.

Ekterly : EPAR - Medicine overview

Reference Number: EMA/261362/2025

English (EN) (121.34 KB - PDF)

**First published:** 08/10/2025

[View](/en/documents/overview/ekterly-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-194)

български (BG) (143.86 KB - PDF)

**First published:**

08/10/2025

[View](/bg/documents/overview/ekterly-epar-medicine-overview_bg.pdf)

español (ES) (120.36 KB - PDF)

**First published:**

08/10/2025

[View](/es/documents/overview/ekterly-epar-medicine-overview_es.pdf)

čeština (CS) (142.25 KB - PDF)

**First published:**

08/10/2025

[View](/cs/documents/overview/ekterly-epar-medicine-overview_cs.pdf)

dansk (DA) (120.23 KB - PDF)

**First published:**

08/10/2025

[View](/da/documents/overview/ekterly-epar-medicine-overview_da.pdf)

Deutsch (DE) (124.16 KB - PDF)

**First published:**

08/10/2025

[View](/de/documents/overview/ekterly-epar-medicine-overview_de.pdf)

eesti keel (ET) (116.98 KB - PDF)

**First published:**

08/10/2025

[View](/et/documents/overview/ekterly-epar-medicine-overview_et.pdf)

ελληνικά (EL) (154.26 KB - PDF)

**First published:**

08/10/2025

[View](/el/documents/overview/ekterly-epar-medicine-overview_el.pdf)

français (FR) (122.2 KB - PDF)

**First published:**

08/10/2025

[View](/fr/documents/overview/ekterly-epar-medicine-overview_fr.pdf)

hrvatski (HR) (143.76 KB - PDF)

**First published:**

08/10/2025

[View](/hr/documents/overview/ekterly-epar-medicine-overview_hr.pdf)

italiano (IT) (119.53 KB - PDF)

**First published:**

08/10/2025

[View](/it/documents/overview/ekterly-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (149.54 KB - PDF)

**First published:**

08/10/2025

[View](/lv/documents/overview/ekterly-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (140.87 KB - PDF)

**First published:**

08/10/2025

[View](/lt/documents/overview/ekterly-epar-medicine-overview_lt.pdf)

magyar (HU) (140.79 KB - PDF)

**First published:**

08/10/2025

[View](/hu/documents/overview/ekterly-epar-medicine-overview_hu.pdf)

Malti (MT) (143.61 KB - PDF)

**First published:**

08/10/2025

[View](/mt/documents/overview/ekterly-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.66 KB - PDF)

**First published:**

08/10/2025

[View](/nl/documents/overview/ekterly-epar-medicine-overview_nl.pdf)

polski (PL) (144.86 KB - PDF)

**First published:**

08/10/2025

[View](/pl/documents/overview/ekterly-epar-medicine-overview_pl.pdf)

português (PT) (120.79 KB - PDF)

**First published:**

08/10/2025

[View](/pt/documents/overview/ekterly-epar-medicine-overview_pt.pdf)

română (RO) (139.08 KB - PDF)

**First published:**

08/10/2025

[View](/ro/documents/overview/ekterly-epar-medicine-overview_ro.pdf)

slovenčina (SK) (141.87 KB - PDF)

**First published:**

08/10/2025

[View](/sk/documents/overview/ekterly-epar-medicine-overview_sk.pdf)

slovenščina (SL) (140.1 KB - PDF)

**First published:**

08/10/2025

[View](/sl/documents/overview/ekterly-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.03 KB - PDF)

**First published:**

08/10/2025

[View](/fi/documents/overview/ekterly-epar-medicine-overview_fi.pdf)

svenska (SV) (118.45 KB - PDF)

**First published:**

08/10/2025

[View](/sv/documents/overview/ekterly-epar-medicine-overview_sv.pdf)

Ekterly : EPAR - Risk management plan

English (EN) (1.47 MB - PDF)

**First published:** 08/10/2025

[View](/en/documents/rmp/ekterly-epar-risk-management-plan_en.pdf)

## Product information

Ekterly : EPAR - Product information

English (EN) (378.84 KB - PDF)

**First published:** 08/10/2025

[View](/en/documents/product-information/ekterly-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-603)

български (BG) (1.11 MB - PDF)

**First published:**

08/10/2025

[View](/bg/documents/product-information/ekterly-epar-product-information_bg.pdf)

español (ES) (1.05 MB - PDF)

**First published:**

08/10/2025

[View](/es/documents/product-information/ekterly-epar-product-information_es.pdf)

čeština (CS) (1.1 MB - PDF)

**First published:**

08/10/2025

[View](/cs/documents/product-information/ekterly-epar-product-information_cs.pdf)

dansk (DA) (415.58 KB - PDF)

**First published:**

08/10/2025

[View](/da/documents/product-information/ekterly-epar-product-information_da.pdf)

Deutsch (DE) (433.2 KB - PDF)

**First published:**

08/10/2025

[View](/de/documents/product-information/ekterly-epar-product-information_de.pdf)

eesti keel (ET) (985.63 KB - PDF)

**First published:**

08/10/2025

[View](/et/documents/product-information/ekterly-epar-product-information_et.pdf)

ελληνικά (EL) (1.06 MB - PDF)

**First published:**

08/10/2025

[View](/el/documents/product-information/ekterly-epar-product-information_el.pdf)

français (FR) (397 KB - PDF)

**First published:**

08/10/2025

[View](/fr/documents/product-information/ekterly-epar-product-information_fr.pdf)

hrvatski (HR) (479.88 KB - PDF)

**First published:**

08/10/2025

[View](/hr/documents/product-information/ekterly-epar-product-information_hr.pdf)

íslenska (IS) (977.61 KB - PDF)

**First published:**

08/10/2025

[View](/is/documents/product-information/ekterly-epar-product-information_is.pdf)

italiano (IT) (431.39 KB - PDF)

**First published:**

08/10/2025

[View](/it/documents/product-information/ekterly-epar-product-information_it.pdf)

latviešu valoda (LV) (496.53 KB - PDF)

**First published:**

08/10/2025

[View](/lv/documents/product-information/ekterly-epar-product-information_lv.pdf)

lietuvių kalba (LT) (485.98 KB - PDF)

**First published:**

08/10/2025

[View](/lt/documents/product-information/ekterly-epar-product-information_lt.pdf)

magyar (HU) (484.39 KB - PDF)

**First published:**

08/10/2025

[View](/hu/documents/product-information/ekterly-epar-product-information_hu.pdf)

Malti (MT) (520.55 KB - PDF)

**First published:**

08/10/2025

[View](/mt/documents/product-information/ekterly-epar-product-information_mt.pdf)

Nederlands (NL) (415.64 KB - PDF)

**First published:**

08/10/2025

[View](/nl/documents/product-information/ekterly-epar-product-information_nl.pdf)

norsk (NO) (412.2 KB - PDF)

**First published:**

08/10/2025

[View](/no/documents/product-information/ekterly-epar-product-information_no.pdf)

polski (PL) (518.29 KB - PDF)

**First published:**

08/10/2025

[View](/pl/documents/product-information/ekterly-epar-product-information_pl.pdf)

português (PT) (449.3 KB - PDF)

**First published:**

08/10/2025

[View](/pt/documents/product-information/ekterly-epar-product-information_pt.pdf)

română (RO) (499.17 KB - PDF)

**First published:**

08/10/2025

[View](/ro/documents/product-information/ekterly-epar-product-information_ro.pdf)

slovenčina (SK) (518.39 KB - PDF)

**First published:**

08/10/2025

[View](/sk/documents/product-information/ekterly-epar-product-information_sk.pdf)

slovenščina (SL) (500.81 KB - PDF)

**First published:**

08/10/2025

[View](/sl/documents/product-information/ekterly-epar-product-information_sl.pdf)

Suomi (FI) (972.64 KB - PDF)

**First published:**

08/10/2025

[View](/fi/documents/product-information/ekterly-epar-product-information_fi.pdf)

svenska (SV) (955.75 KB - PDF)

**First published:**

08/10/2025

[View](/sv/documents/product-information/ekterly-epar-product-information_sv.pdf)

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ekterly : EPAR - All authorised presentations

English (EN) (61.74 KB - PDF)

**First published:** 08/10/2025

[View](/en/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-804)

български (BG) (66.46 KB - PDF)

**First published:**

08/10/2025

[View](/bg/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_bg.pdf)

español (ES) (57.78 KB - PDF)

**First published:**

08/10/2025

[View](/es/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_es.pdf)

čeština (CS) (56.84 KB - PDF)

**First published:**

08/10/2025

[View](/cs/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (56.33 KB - PDF)

**First published:**

08/10/2025

[View](/da/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (58.84 KB - PDF)

**First published:**

08/10/2025

[View](/de/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (56.87 KB - PDF)

**First published:**

08/10/2025

[View](/et/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.98 KB - PDF)

**First published:**

08/10/2025

[View](/el/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_el.pdf)

français (FR) (56.14 KB - PDF)

**First published:**

08/10/2025

[View](/fr/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (73.4 KB - PDF)

**First published:**

08/10/2025

[View](/hr/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (57.86 KB - PDF)

**First published:**

08/10/2025

[View](/is/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_is.pdf)

italiano (IT) (55.81 KB - PDF)

**First published:**

08/10/2025

[View](/it/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (73.56 KB - PDF)

**First published:**

08/10/2025

[View](/lv/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (74.42 KB - PDF)

**First published:**

08/10/2025

[View](/lt/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (74.92 KB - PDF)

**First published:**

08/10/2025

[View](/hu/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (74.92 KB - PDF)

**First published:**

08/10/2025

[View](/mt/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (56.49 KB - PDF)

**First published:**

08/10/2025

[View](/nl/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (56.1 KB - PDF)

**First published:**

08/10/2025

[View](/no/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_no.pdf)

polski (PL) (65.72 KB - PDF)

**First published:**

08/10/2025

[View](/pl/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.11 KB - PDF)

**First published:**

08/10/2025

[View](/pt/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_pt.pdf)

română (RO) (74.49 KB - PDF)

**First published:**

08/10/2025

[View](/ro/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (73.26 KB - PDF)

**First published:**

08/10/2025

[View](/sk/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (73.13 KB - PDF)

**First published:**

08/10/2025

[View](/sl/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (55.71 KB - PDF)

**First published:**

08/10/2025

[View](/fi/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (55.55 KB - PDF)

**First published:**

08/10/2025

[View](/sv/documents/all-authorised-presentations/ekterly-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ekterly Active substance sebetralstat International non-proprietary name (INN) or common name sebetralstat Therapeutic area (MeSH) Angioedemas, Hereditary Anatomical therapeutic chemical (ATC) code B06AC08

### Pharmacotherapeutic group

Other hematological agents

### Therapeutic indication

Ekterly is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.

## Authorisation details

EMA product number EMEA/H/C/006211

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Kalvista Pharmaceuticals (Ireland) Limited

10 Earlsfort Terrace Dublin 2 Co. Dublin D02 T380 IRELAND

Opinion adopted 24/07/2025 Marketing authorisation issued 17/09/2025

## Assessment history

## Initial marketing authorisation documents

Ekterly : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-2331715

English (EN) (1.24 MB - PDF)

**First published:** 08/10/2025

[View](/en/documents/orphan-maintenance-report/ekterly-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Ekterly : EPAR - Public assessment report

Adopted

Reference Number: EMA/266036/2025

English (EN) (1.95 MB - PDF)

**First published:** 08/10/2025

[View](/en/documents/assessment-report/ekterly-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ekterly

Adopted

Reference Number: EMA/CHMP/172918/2025

English (EN) (133.46 KB - PDF)

**First published:** 25/07/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ekterly_en.pdf)

#### News on Ekterly

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-july-2025) 25/07/2025

#### More information on Ekterly

- [EU/3/22/2625 - orphan designation for treatment of hereditary angioedema](/en/medicines/human/orphan-designations/eu-3-22-2625)

**This page was last updated on** 08/10/2025

## Share this page

[Back to top](#main-content)